secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039072
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q2 net loss $35.2M; GA visual function data; GBS enrollment completion in H2 2023
--------------------------------------------------------------------------------

- ANX007 (GA) ARCHER Phase 2 data showed dose-dependent preservation of visual function; regulatory engagement planned.
- Phase 3 pivotal trial of ANX005 in GBS enrollment to complete in H2 2023; topline results expected H1 2024.
- Appointed Jamie Dananberg, M.D., as CMO; brings >20 years of drug development experience.
- Cash and equivalents $192.9M as of June 30, providing runway into 2025. Q2 net loss $35.2M ($0.47 per share).
- Upcoming catalysts: ANX1502 Phase 1a data (H2 2023), ANX009 LN Phase 1b data, ALS Phase 2a data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/0000950170-23-039072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/annx-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer